Palbociclib Plus Letrozole in Hormone Receptor Positive Residual Disease After Neoadjuvant Chemotherapy

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

November 21, 2019

Primary Completion Date

January 26, 2022

Study Completion Date

February 24, 2022

Conditions
Breast Cancer
Interventions
DRUG

Palbociclib

Palbociclib 125 mg once daily, day 1 to day 21, followed by 7 days off treatment in a 28-day cycle

DRUG

Letrozole

Letrozole: oral, 2.5 mg per day continuously. during the 28-day cycle.

Trial Locations (8)

Unknown

Hospital General de Catalunya, Barcelona

ICO Hospitalet, Barcelona

Hospital 12 de octubre, Madrid

Hospital Universitario Infanta Sofía, Madrid

Hospital Virgen de la Victoria, Málaga

Hospital Son Espases, Palma de Mallorca

Complejo Hospitalario Santiago de Compostela (CHUS), Santiago de Compostela

Hospital Virgen del Rocío, Seville

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

SOLTI Breast Cancer Research Group

OTHER